Overview
Seelos Biosciences is a clinical-stage company developing intranasal racemic ketamine (SLS-002) for acute suicidal ideation and behavior in major depressive disorder. They have a broader pipeline targeting CNS and rare disease indications.
More in Mental Health Tech
Latest industry news
Closed-Loop BCIs Charted as Next Frontier for Depression, Anxiety, and PTSD Treatment
2026-07-21 · Research
Instruments of Self-Knowledge: How Cognitive Assessment Tech Is Making the Invisible Mind Measurable
2026-07-21 · Industry
Top 10 Technologies Turning Self-Awareness Into Something You Can Actually See
2026-07-21 · Industry
China Clears Brain-Computer Interfaces for Commercial Use, Prompting Calls for Global Regulatory Alignment
2026-07-20 · Policy
Company details
Category
💙 Mental Health Tech
Location
New York, USA
Funding
Public · NASDAQ: SEEL
Website
seelosbio.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →